ALDOA and myeloproliferative disorder: With the single use of Jak2 mutation screening assay (tetra primer assay), only 60% (63/105) of MPN patients were identified, but with the combinatory uses of Jak2 mutation screening and PCR-ALDA assays, 71.4% (75/105) of patients were diagnosed during hospitalization.